Literature DB >> 35655113

Quantitative single photon emission computed tomography derived standardized uptake values on 99mTc-PYP scan in patients with suspected ATTR cardiac amyloidosis.

Juan Carlo Avalon1, Jacob Fuqua1, Seth Deskins1, Tyler Miller1, Justin Conte1, Daniel Martin2, Gary Marano2, Naveena Yanamala3, James Mills3, Christopher Bianco3, Brijesh Patel3, Karthik Seetharam3, Raymond Raylman2, Partho P Sengupta4, Yasmin S Hamirani5.   

Abstract

Technetium-99 pyrophosphate scintigraphy (99mTc-PYP) provides qualitative and semiquantitative diagnosis of ATTR cardiac amyloidosis (ATTR-CA) using the Perugini scoring system and heart/contralateral heart ratio (H/CL) on planar imaging. Standardized uptake values (SUV) with quantitative single photon emission computed tomography (xSPECT/CT) can offer superior diagnostic accuracy and quantification through precise myocardial contouring that enhances assessment of ATTR-CA burden. We examined the correlation of xSPECT/CT SUVs with Perugini score and H/CL ratio. We also assessed SUV correlation with cardiac magnetic resonance (CMR), echocardiographic, and baseline clinical characteristics. Retrospective review of 78 patients with suspected ATTR-CA that underwent 99mTc-PYP scintigraphy with xSPECT/CT. Patients were grouped off Perugini score (Grade 0-1 and Grade 2-3), H/CL ratio (≥ 1.5 and < 1.5). Two cohorts were also created: myocardium SUVmax > 1.88 and ≤ 1.88 at 1-hour based off an AUC curve with 1.88 showing the greatest sensitivity and specificity. Cardiac SUV retention index was calculated as [SUVmax myocardium/SUVmax vertebrae] × SUVmax paraspinal muscle. Primary outcome was myocardium SUVmax at 1-hour correlation with Perugini grades, H/CL ratio, CMR, and echocardiographic data. Higher Perugini Grades corresponded with higher myocardium SUVmax values, especially when comparing Perugini Grade 3 to Grade 2 and 1 (3.03 ± 2.1 vs 0.59 ± 0.97 and 0.09 ± 0.2, P < 0.001). Additionally, patients with H/CL ≥ 1.5 had significantly higher myocardium SUVmax compared to patients with H/CL ≤ 1.5 (2.92 ± 2.18 vs 0.35 ± 0.60, P < 0.01). Myocardium SUVmax at 1-hour strongly correlated with ECV (r = 0.91, P = 0.001), pre-contrast T1 map values (r = 0.66, P = 0.037), and left ventricle mass index (r = 0.80, P = 0.002) on CMR. SUVs derived from 99mTc-PYP scintigraphy with xSPECT/CT provides a discriminatory and quantitative method to diagnose and assess ATTR-CA burden. These findings strongly correlate with CMR.
© 2022. The Author(s) under exclusive licence to American Society of Nuclear Cardiology.

Entities:  

Keywords:  Amyloid; Cardiooncology; Heart failure; Multimodality imaging; Nuclear imaging; Radiology

Year:  2022        PMID: 35655113     DOI: 10.1007/s12350-022-02988-5

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  20 in total

1.  Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States.

Authors:  Lauren G Gilstrap; Francesca Dominici; Yun Wang; M Samir El-Sady; Amitoj Singh; Marcelo F Di Carli; Rodney H Falk; Sharmila Dorbala
Journal:  Circ Heart Fail       Date:  2019-06-07       Impact factor: 8.790

2.  Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis.

Authors:  Claudio Rapezzi; Candida C Quarta; Pier Luigi Guidalotti; Cinzia Pettinato; Stefano Fanti; Ornella Leone; Alessandra Ferlini; Simone Longhi; Massimiliano Lorenzini; Letizia Bacchi Reggiani; Christian Gagliardi; Pamela Gallo; Caterina Villani; Fabrizio Salvi
Journal:  JACC Cardiovasc Imaging       Date:  2011-06

3.  Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: a bivariate meta-analysis.

Authors:  Giorgio Treglia; Andor W J M Glaudemans; Francesco Bertagna; Bouke P C Hazenberg; Paola A Erba; Raffaele Giubbini; Luca Ceriani; John O Prior; Luca Giovanella; Riemer H J A Slart
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-04-23       Impact factor: 9.236

4.  Role of cardiac scintigraphy with ⁹⁹mTc-DPD in the differentiation of cardiac amyloidosis subtype.

Authors:  F Javier de Haro-del Moral; Alicia Sánchez-Lajusticia; Manuel Gómez-Bueno; Pablo García-Pavía; Clara Salas-Antón; Javier Segovia-Cubero
Journal:  Rev Esp Cardiol (Engl Ed)       Date:  2012-03-30

5.  (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses.

Authors:  Sabahat Bokhari; Adam Castaño; Ted Pozniakoff; Susan Deslisle; Farhana Latif; Mathew S Maurer
Journal:  Circ Cardiovasc Imaging       Date:  2013-02-11       Impact factor: 7.792

Review 6.  Nuclear imaging modalities for cardiac amyloidosis.

Authors:  Sabahat Bokhari; Reehan Shahzad; Adam Castaño; Mathew S Maurer
Journal:  J Nucl Cardiol       Date:  2014-02       Impact factor: 5.952

Review 7.  Transthyretin (TTR) cardiac amyloidosis.

Authors:  Frederick L Ruberg; John L Berk
Journal:  Circulation       Date:  2012-09-04       Impact factor: 29.690

8.  Tc-HDP quantitative SPECT/CT in transthyretin cardiac amyloid and the development of a reference interval for myocardial uptake in the non-affected population.

Authors:  Stuart C Ramsay; Karen Lindsay; William Fong; Shaun Patford; John Younger; John Atherton
Journal:  Eur J Hybrid Imaging       Date:  2018-08-22

9.  Diagnosing Transthyretin Cardiac Amyloidosis by Technetium Tc 99m Pyrophosphate: A Test in Evolution.

Authors:  Timothy J Poterucha; Pierre Elias; Sabahat Bokhari; Andrew J Einstein; Albert DeLuca; Mona Kinkhabwala; Lynne L Johnson; Kathleen R Flaherty; Sunil E Saith; Jan M Griffin; Adler Perotte; Mathew S Maurer
Journal:  JACC Cardiovasc Imaging       Date:  2020-11-18

Review 10.  Diagnosis of Transthyretin Amyloid Cardiomyopathy.

Authors:  Adam S Hafeez; Anthony A Bavry
Journal:  Cardiol Ther       Date:  2020-04-07
View more
  1 in total

1.  Quantitation in ATTR cardiac amyloidosis: the next step is almost there!

Authors:  Gabriel Blacher Grossman
Journal:  J Nucl Cardiol       Date:  2022-07-19       Impact factor: 3.872

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.